Poolbeg Pharma PLC (LON:POLB – Get Free Report) dropped 0.8% on Monday . The company traded as low as GBX 3.80 ($0.05) and last traded at GBX 3.90 ($0.05). Approximately 713,419 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 2,085,585 shares. The stock had previously closed at GBX 3.93 ($0.05).
Poolbeg Pharma Stock Performance
The stock has a market cap of £27.19 million, a PE ratio of -336.21 and a beta of 2.11. The stock has a fifty day simple moving average of GBX 3.27 and a two-hundred day simple moving average of GBX 3.08.
Insiders Place Their Bets
In related news, insider Cathal Friel purchased 4,000,000 shares of the firm’s stock in a transaction on Wednesday, June 25th. The stock was purchased at an average price of GBX 3 per share, for a total transaction of £120,000. 7.65% of the stock is currently owned by corporate insiders.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).
Recommended Stories
- Five stocks we like better than Poolbeg Pharma
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How The Weak Dollar Is Fueling These Global Stock Surges
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Recession-Ready Stocks That Thrive When the Economy Sputters
- Where Do I Find 52-Week Highs and Lows?
- 3 Automation-Focused Stocks Flying Under the Radar
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
